SAN DIEGO, Nov. 1, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at two high-profile events in November: 31st Annual Meeting & Associated Programs of the Society for Immunotherapy of Cancer ("SITC") and the Stifel Nicolaus Weisel Healthcare Conference 2016.
31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Dr. Alain Algazi, Clinical Instructor, Department of Medicine (Hematology/Oncology) at the University of California San Francisco (UCSF), will present an oral poster presentation for Abstract #466 on November 11, 2016 at 12:50 PM (EST) in National Harbor, MD. The title of the poster is "Phase II Study of Intratumoral Plasmid Interleukin 12 (pIL-12) with Electroporation in Combination with Pembrolizumab in Stage III/IV Melanoma Patients with Low Tumor Infiltrating Lymphocytes." The SITC conference brings together leading scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world that are dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. For more information, please visit: http://www.sitcancer.org/2016.
Dr. Algazi, the Principal Investigator for the Phase II Investigator Sponsored Trial (IST) led by UCSF, will be presenting new clinical data from patients treated with a combination of OncoSec's investigational intratumoral therapy, ImmunoPulse® IL-12, and Merck's KEYTRUDA® (pembrolizumab). Patients who had unresectable metastatic melanoma and were assessed as unlikely to respond to anti-PD1 monotherapy, were selected to participate in the Investigator Sponsored Trial (IST). This oral poster presentation will provide an interim update of 15 treated patients. Further details on this SITC oral poster presentation will be provided in upcoming Company communications.
Stifel Nicolaus Weisel Healthcare Conference 2016
OncoSec's CEO, Mr. Punit Dhillon, will present a corporate overview at the Stifel Conference on November 15, 2016, at 11:00 AM EST, in New York City. This conference provides a forum for institutional investors to connect with senior management and industry experts, and serves as a showcase for dynamic emerging companies in the healthcare industry. For more information, please visit: http://www.stifel.com/institutional/ConferenceAndEvents.
To view the live webcast, please use the following link: http://wsw.com/webcast/stifel5/oncs. An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com.
OncoSec Investor & Analyst Day
In addition, OncoSec recently announced that it will be hosting its inaugural Investor & Analyst Day in San Diego, on November 17, 2016. The event will be webcast live beginning at 8:00 AM PST. The live webcast can be accessed at: http://edge.media-server.com/m/p/i6ug66hu, and will be available for replay on the Company website.
This event will provide a forum for the Company to share updates on its clinical development plan for melanoma, advancement of its intratumoral immunotherapy pipeline of DNA-based product candidates, and next generation device development. For more information, please visit: http://ir.oncosec.com/press-releases/detail/1883/oncosec-to-host-investor-analyst-day-on-november-17-2016
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several indications, including metastatic melanoma, head and neck cancer, and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.
Sophia Ononye, PhD MPH MBA
Associate Director, Investor Relations and Corporate Communications
OncoSec Medical Incorporated
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-scientific-and-investment-conferences-and-to-host-inaugural-investor-and-analyst-day-in-november-300354589.html
SOURCE OncoSec Medical Incorporated